Missing Audit Trail Review led to Warning Letter
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
This FDA Warning Letter issued to pharmaceutical manufacturer Zhejiang Ludao Technology Co., Ltd. on 23 February, 2018 is based on an FDA inspection which took place in August 2017.
It came to light during the inspection that the analytical testing results of four batches of finished products could not be provided.
Furthermore, there were three data files found in the electronic recycle bin of the stand-alone HPLC system which had been used to test a manufactured spray. Since this HPLC system had no Audit Trail capabilities, it could not be said how frequently test data had been deleted before an "official" test result was declared.
The company's response was not sufficient in the eye of the FDA: Zhejiang Ludao Technology conducted no retrospective evaluation of the extent of insufficient data retention. The effect on other electronic systems had not been evaluated, either. The response particularly lacked details on the validation and the Audit Trail Review possibilities of the new HPLC system.
Please also read the complete FDA warning letter to Zhejiang Ludao Technology Co., Ltd..
Related GMP News
03.02.2026Your Input is Requested: AQCG Survey on OOS Investigations
03.02.2026Questions and Answers on System Suitability Tests (SST) - Part 2
03.02.2026Eurachem Publishes New Guide on the Fitness for Intended Use of Analytical Equipment and Systems
14.01.2026FDA Warning Letter: OOS Handling and HPLC Method Validation
07.01.2026Revised Ph. Eur. Chapters 2.9.42 and 2.9.43 on Dissolution Testing
07.01.2026Korean MFDS Publishes Data Collection on Dissolution Test Methods